Underweight: 10-15% trim at current levels, maintain core through Q3 earnings binary catalyst with volatility-based stop
Underweight maintained with immediate 10-15% trim. Technical deterioration (50-SMA broken, MACD -9.98 for 7 sessions, RSI 43.37, price below 10-EMA and 50-SMA), unresolved valuation gap (38.9x trailing P/E vs 26.2% EPS growth), and structural GLP-1 concentration risk support trim. Core position maintained through Q3 earnings because binary catalyst unresolved and structural metrics (54% operating margins, 102% ROE, $11B FCF) argue against full exit. 200-SMA cushion at $1,059 (~9% below current) provides structural support. Full exit only on close <$1,059 on >4M volume.
| Position | Action |
|---|---|
| Current levels ($1,155-$1,170) | Trim 10-15% of LLY position immediately — no contingent setup, no waiting for relief rally |
| Core position maintenance | Maintain ~85-90% core position through Q3 2026 earnings binary catalyst (~6 weeks out) |
| Volatility stop | Stop at $1,100 close (1.5x ATR) |
| Structural exit | Exit only at close <$1,059 on >4M volume |
| Tier-1 re-engagement | MACD contraction from trough toward -5.00 with RSI>45 |
| Tier-2 add zone | $1,070-$1,090 (200-SMA zone) with confirmation |
| Tier-3 flush add | $1,020-$1,040 |
| Tier-4 re-engagement | Close >$1,190 on >3M volume |
LLY's 9.4% pullback to $1,159 represents a high-quality buying opportunity within a confirmed long-term uptrend, backed by exceptional Q2 2026 fundamentals (47.7% revenue growth, 77.4% operating income growth, $11.07B FCF) and technical indicators historically marking short-term bottoms.
| Indicator | Value | Signal |
|---|---|---|
| 10-EMA | 1,180.57 | bearish |
| 50-SMA | 1,189.88 | bearish |
| 200-SMA | 1,059.71 | bullish |
| MACD Line | -4.89 | bearish |
| MACD Signal Line | 4.75 | bearish |
| MACD Histogram | -9.63 | bearish |
| RSI (14-period) | 43.37 | bearish |
| Bollinger Upper Band | 1,277.42 | neutral |
| Bollinger Middle Band (20-SMA) | 1,203.98 | neutral |
| Bollinger Lower Band | 1,130.54 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Re-engage on MACD contraction from current trough toward -5.00 with RSI>45 (per 9/1 LLY lesson)
Fundamental growth is exceptional and validating elevated valuation
↩ rebuts: “Valuation is stretched and stock near 52-week high”
EV: +17.3% to upper Bollinger Band $1,277 from $1,159; +3.9% to $1,204 Bollinger middle band; +6.1% to $1,230 August high · concedes: Technical bearish signals (MACD cross, RSI below 50, below 10-EMA and 50-SMA) are real concerns; Debt of $54.91 billion with 162% debt-to-equity is genuinely elevated; Trump/RFK drug pricing risk is a legitimate sector-wide headwind; Stock at 52-week high creates near-term resistance psychology; Near-term volatility is real even if long-term thesis holds; The HOLD recommendations from technical and fundamentals reports reflect reasonable caution
LLY's extreme valuation (38.9x trailing P/E, roughly double sector median) combined with broken technicals, EPS growth of only 26% versus 58% priced in, accelerating debt load ($54.91B, net debt up $11.58B in Q2 alone), and structural threats to GLP-1 pricing power creates unfavorable risk/reward at current levels, warranting HOLD rather than BUY until a pullback to the 200-SMA at $1,059.
· concedes: The fundamentals are excellent; The forward P/E of 24.5x is the strongest bull argument; Revenue growth (47.7%) and operating income growth (77.4%) are genuinely strong; Operating cash flow is enormous; The company is a great company — just not a great entry point at current levels; Wait for 200-SMA retest at $1,059 where risk/reward becomes asymmetric
→ vs conservative: 200-SMA at $1,059 being 'the line that matters' with long-term uptrend intact is exactly what bulls said at every prior major top before trend broke; waiting for 200-SMA breach means accepting a 20% drawdown
→ vs conservative: 'Don't trim into weakness' is how you give back gains; LLY is up 88% and technical regime is shifting
→ vs neutral: Technical report admits short-term bearish, medium-term broken, MACD deteriorating across every timeframe — 'hold for existing holders, wait for new entries' is a contradiction when picture is deteriorating across all timeframes
→ vs neutral: Waiting for confirmation is how you turn a 10% drawdown into a 20% one; active trim into resistance is the aggressive move
→ vs conservative: Bullish institutional sentiment at deteriorating technical posture means smart money already positioned and easy money made; sentiment is a contrary indicator here
→ vs neutral: Fundamental analyst acknowledging 'fundamentally outstanding, HOLD' ignores that valuation gap at 38.9x P/E vs 26.2% growth is real; strong fundamentals justify staying invested, not maintaining max exposure into deteriorating price action
| ATR (14-period) | 36.48 | neutral |
Support: 1159.6 · 1130.54 · 1059.71 | Resistance: 1180.57 · 1189.88 · 1203.98 · 1230.18 · 1277.42
The technical posture is short-term bearish / medium-term neutral / long-term constructive. The recommendation is a HOLD situation for existing long-term holders (price still above 200-SMA) but a WAIT for new entries. RSI at 43.37 is approaching the 40 level, which historically marks short-term bottoms. ATR is elevated at $36.48 (~3.15% of price), suggesting elevated volatility and wider stop-loss placement. Support sits at $1,159.60 (current price/psychological), $1,130.54 (lower Bollinger Band), and $1,059.71 (200-SMA critical level). Resistance is at $1,189.88 (50-SMA), $1,203.98 (Bollinger middle), $1,230.18 (August 10 high), and $1,277.42 (upper Bollinger Band).
Market Cap
$1,034.06 B
Share Price
~$1,160
52-Week High
$1,292.65
52-Week Low
$712.05
50-Day Moving Average
$1,190.22
200-Day Moving Average
$1,062.02
Beta
0.506
Dividend Yield
0.60%
Shares Outstanding
893.67 M
P/E (TTM)
38.90x
Forward P/E
24.54x
PEG Ratio
1.12
P/B
30.51x
EPS (TTM)
$29.81
Forward EPS
$47.26
Revenue (TTM)
$79.67 B
Gross Profit (TTM)
$66.44 B
EBITDA (TTM)
$41.71 B
Net Income (TTM)
$26.71 B
Gross Margin
83.4%
Operating Margin
54.2%
Net Profit Margin
33.5%
ROE
102.3%
ROA
20.4%
Total Assets (Q2'26)
$142.28 B
Total Equity (Q2'26)
$33.88 B
Total Debt (Q2'26)
$54.91 B
Net Debt (Q2'26)
$45.96 B
Current Ratio (Q2'26)
1.36
Debt/Equity
162%
Free Cash Flow (TTM)
$11.07 B
Revenue Growth (2025 YoY)
+44.7%
Net Income Growth (2025 YoY)
+94.9%
EPS Growth (2025 YoY)
+96.0%
Revenue Growth (Q2'26 YoY)
+47.7%
Operating Income Growth (Q2'26 YoY)
+77.4%
EPS Growth (Q2'26 YoY)
+26.2%
Strengths
Concerns
Eli Lilly reported best-in-class pharma fundamentals with revenue doubling from $34.1B (2023) to $65.2B (2025) and net income quadrupling to $20.6B, powered by tirzepatide franchise (Mounjaro/Zepbound). Operating margins expanded dramatically from 30.2% to 45.6% over the same period, reaching 54.2% TTM, while ROE hit 102.3% — reflecting exceptional capital efficiency on the GLP-1 product cycle. The balance sheet leveraged up to fund $8.75B in M&A and $16B+ TTM capex, with debt-to-equity at 162%, but $11.07B TTM FCF demonstrates cash generation now comfortably covers obligations.
Macro: Fed signaling a 'higher-for-longer' stance with only 1% priced for Sept 2026 cut, 12% by Dec 2026 (Polymarket). US recession odds at 8% (down 1pp WoW), supporting soft-landing consensus. A defensive bid is supporting healthcare/Big Pharma even as tight liquidity backdrop historically compresses high-multiple stocks. Precious metals rally (gold up, silver jumping after 'short-lived' regional airstrikes) signals residual geopolitical tail-risk hedging. Walmart up ~2.8% on expanded DOJ beef-pricing probe — fresh evidence that drug-pricing enforcement is a 2026 political theme overlapping with Trump's MFN expansion.